108 results about "Azulene" patented technology

This invention relates to CCK-A agonists of Formula (I) wherein R1-R4, A, B, X, D, E and G are as defined in the specificiation, as well as, among other things, pharmaceutical compositions containing the compounds and methods of use of the compounds and compositions. The compounds are useful in treating obesity.

A process for producing an azulene derivative useful as a Na+-glucose cotransporter inhibitor, which is high in yield, is simple in operation, is low in cost, is suited for environmental protection, and is advantageous industrially, the process being characterized by reducing and deprotecting at least one compound selected from penta-acyl compounds and tetra-acyl compounds or salts thereof to obtain a C-glycoside compound; and a useful intermediate for synthesis of such an azulene derivative, obtained in the course of the above process.

The present invention provides substituted 10,11-Dihydro-5H-benzo[e]-pyrrolo[1,2-a][1,4]diazepine and 9,10-Dihydro-4H-3a,5,9-triaza-benzo[f]azulene compounds as well as methods and pharmaceutical compositions utilizing these compounds for the treatment and / or prevention and / or suppression of disorders which may be remedied or alleviated by oxytocin antagonist activity, including prevention and / or suppression of preterm labor, suppression labor at term prior to caesarean deliver, and for the treatment of dysmenorrhea. These compounds are also useful in enhancing fertility rates, enhancing survival rates and synchronizing estrus in farm animals.

This invention relates to CCK-A agonists of Formula (I)wherein R1-R4, A, B, X, D, E and G are as defined in the specificiation, as well as, among other things, pharmaceutical compositions containing the compounds and methods of use of the compounds and compositions. The compounds are useful in treating obesity.

The present invention relates to heterobiaryl-cyclohexyl-tetraazabenzo[e]azulenes of formula Iwherein R1, R2 and R3 are as described herein. The compounds according to the invention act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

The present invention is concerned with aryl- / heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes of formula Iwherein R1, R2 and R3 are as described herein. The invention further provides methods for the manufacture of such compounds and pharmaceutical compositions containing them. The compounds according to the invention act as V1 a receptor modulators, and in particular as V1 a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

The present invention is concerned with heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes of formula Iwherein R1, R2 and R3 are as described herein.The compounds according to the invention act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

The stable synthesis technique for sodium azulenesulfonate comprises: using SB102 and C2H4Cl2 for weak complex reaction with SO3; taking the former product and azulene for sulfonation with SB102; cooling the liquid; separating the organic solvent from the liquid; fractionating in fractionator to discharge water; cleaning the resultant; drying, recrystallizing with stabilizer, and obtaining the product. This invention has no toxic operation, and reduces pollution.

A composition used as gastric mucosa protecting agent for treating acute or chronic gastritis, gastric ulcer, duodenal ulcer, etc is prepared from the water-soluble precursors including sodium azulenesulfonate and L-glutamine or glycyl-L-glutamine or L-alanyl-L-glutamine through proportioning and conventional steps.

A choline salt crystal of (1S)-1,5-anhydro-1-[5-(azulen-2-ylmethyl)-2-hydroxyphenyl]-D-glucitol which shows an endothermic peak at 194 to 198° C. as measured by differential scanning calorimetry (DSC analysis) and shows main peaks at about 2θ (°) 5.58, 14.72, 16.80, 17.82, 21.02, and 22.46 as measured by X-ray powder diffraction. Thus, a crystal of an azulene compound can be produced which is in a single crystal form, has a constant quality, can be produced with good reproducibility, can be provided stably as a crystal of an drug substance for use in the preparation of a pharmaceutical and is excellent in storage stability.

The invention provides a compound buccal tablet containing sodium azulene sulfonate and an application. The compound buccal tablet containing the sodium azulene sulfonate comprises the following components by weight percent: 0.2 to 1 percent of sodium azulene sulfonate, 80 to 89 percent of dedicated Chinese herbal medicinal extract, 3 to 20 percent of white sugar, 1 to 25 percent of fructose, 2 to 5 percent of povidone, and 0.5 to 1.5 percent of sucrose ester, wherein the dedicated Chinese herbal medicinal extract is extracted from dwarf lilyturf tuber, figwort root, fragrant solomonseal, lily, burdock, mint, boat-fruited sterculia seed and reed root. The application of the compound buccal table containing the sodium azulene sulfonate includes treatment of pharyngitis, glossitis, chronic tonsillitis, periodontitis, oral cavity ulcer and other oral cavity diseases, so that discomfortable symptoms caused by oral cavity diseases can be effectively relieved. The sodium azulene sulfonate is compounded with the dedicated Chinese herbal medicinal extract to achieve the aims of quickly treating pharyngitis, glossitis, chronic tonsillitis, periodontitis, oral cavity ulcer and other oral cavity diseases, and various discomfortable symptoms caused by the diseases can be effectively relieved.

The invention discloses sodium azulene sulfonate gel. The sodium azulene sulfonate gel is prepared from 0.05-1 weight part of sodium azulene sulfonate, 0.5-50 weight parts of a gel base material, 1-50 weight parts of a transdermal enhancer, 0.5-2.5 weight parts of a pH conditioning agent, 0.1-0.5 weight parts of an antiseptic and 40-65 weight parts of a solvent. The invention also provides a preparation method and a use of the sodium azulene sulfonate gel. The sodium azulene sulfonate gel has the advantages of good appearance, good coating performances, use convenience, good biocompatibility with skin, no irritation and no pollution on clothes, and has strong skin adhesion, good permeability and a high concentration on local skin.

The invention belongs to the technical field of cosmetic, and more specifically relates to a hyaluronic acid facial mask liquid, and a manufacturing method thereof. The hyaluronic acid facial mask liquid is prepared from, by mass, 0.08 to 0.12% of carbomer 940, 0.09 to 0.12% of hydroxyethyl cellulose, 0.2 to 0.5% of hyaluronic acid, 0.2 to 0.5% of sodium hyaluronate, 0.2 to 0.5% of hydrolyzed Hyaluronic Acid, 0.2 to 0.5% of acetylated sodium hyaluronate, 3.8 to 4.2% of dipropylene glycol, 1.8 to 2.1% of propylene glycol, 1.8 to 2.2% of glycerin, 3 to 5% of a sodium azulene sulfonate solution,0.4 to 0.6% of GC-04, 0.09 to 0.11% of triethanolamine, 0.01 to 0.02% of an essence, and 83.53 to 88.13% of deionized water. The hyaluronic acid facial mask liquid is capable of supplying water, improving skin physiological conditions, reinforcing skin nutrient supply, preventing ageing and skin oxidation, removing wrinkles, and improving face contour.

A calosoma maximoviczi morawitz attractant is characterized by mainly prepared through mixing the following materials in percentage by weight: 20%-70% of beta-trans-ocimene, 10%-50% of alpha-farnesene, 1%-10% of linalool, 1%-10% of paraethyl acetophenone, 1%-10% of azulene, 1%-10% of cis-3-hexenyl-acetate, 1%-10% of cis-3-hexenyl-1-alcohol, 1%-10% of n-tetradecane, 1%-10% of n-pentdecne and 1%-10% of n-heneicosane. The calosoma maximoviczi morawitz attractant and a lure core are high in sensitivity, free of environment pollution and low in cost, thereby having higher popularization and application values and displaying higher trapping activity in the field.

The invention belongs to the technical field of medicine, and discloses an azulene compound as well as a preparation method and application thereof, the compound comprises two azulene compounds which are mutually isomeride, and the chemical name of the azulene compound is 8-(1, 2-dihydroxypropane-2-yl)-2-hydroxy-1, 10-dimethyl-9-dihydroazulene-3, 4-diketone. The preparation method of the compounds is simple to operate, pure compounds can be obtained through separation, and experiments show that the two compounds have no obvious influence on growth of RAW 264.7 macrophages within 24 h, NO release of LPS-induced RAW 264.7 cells can be obviously inhibited, excessive secretion of IL-1beta, IL-6 and TNF-alpha in the cells can be inhibited, and the compounds have an obvious anti-inflammatory effect.

The invention discloses azulene-sulfonate-containing gynaecological special lotion. The gynaecological special lotion is prepared from azulene sulfonate and metronidazole, wherein every 500 millimetres of lotion comprises 0.05 to 2.5 grams of azulene sulfonate, 1 to 3 grams of metronidazole and the balance of pure water, and further comprises golden cypress, radix sophorae flavescentis, common cnidium fruit and rhizoma atractylodis, wherein every 500 millimetres of lotion comprises 0.05 to 2.5 grams of azulene sulfonate, 1 to 3 grams of metronidazole, 5 to 10 grams of golden cypress, 5 to 10 grams of radix sophorae flavescentis, 10 to 25 grams of common cnidium fruit, 5 to 10 grams of rhizoma atractylodis and the balance of pure water. The azulene sulfonate-containing gynaecological special lotion is easy to prepare and convenient to use, has good effects of diminishing inflammation and relieving itching, can resist bacteria strikingly without side effects, and cannot stimulate mucous membranes and skins. Furthermore, the lotion can relieve and eliminate various unwell symptoms of women caused by episioitis and vaginitis, and also can improve the self disease resistance of a female reproductive system.

The invention belongs to the technical field of fluorochrome and particularly relates to nitrile-group-containing azulene-styrene derivatives as well as a preparation method and an application of the nitrile-group-containing azulene-styrene derivatives. The nitrile-group-containing azulene-styrene derivatives are 3-(1-azulene)-2-(4-hydroxyphenyl) acrylonitrile derivatives obtained through introduction of azulene into a nitrile styrene structure, has an efficient response property to acid, has remarkably enhanced fluorescence after acting with the acid, can be used as an outstanding pH fluorescence enhanced probe and can be used for detecting pH value in water, soil and organisms. Besides, compounds formed by the derivatives and the acid also respond to ultraviolet light, very strong signals are generated in a near-infrared region after irradiation with ultraviolet light, and the compounds can be used as excellent near-infrared fluorochrome to be used for fluorescence labeling in the organisms and cells.

The invention relates to a muscular soreness relieving and massaging cream and a preparing method thereof. The muscular soreness relieving and massaging cream is prepared from various bioactive constituents including chavicol methylether, matricaria azulene, alpha-bisabol, sesquiterpene lactone, menthol, menthone, citral and the like. The muscular soreness relieving and massaging cream has the main effect of rejuvenating the musculoskeletal system, and has the functions of diminishing inflammation, relieving pain, recovering muscles, the brain, the heart and the elasticity of the skin and the like. The muscular soreness relieving and massaging cream is suitable for rheumatism, arthritis and muscular soreness. Essential oil of the muscular soreness relieving and massaging cream is prepared from essence extracted from plants, and is natural, organic, free of any artificially-synthesized constituent, free of removal of any original constituent, free of decloration, free of rectification and free of over oxidation. Thus, the muscular soreness relieving and massaging cream is free of toxic or side effects on the human body. In addition, due to the fact that chemical molecules are small and are lipid soluble molecules, the muscular soreness relieving and massaging cream can quickly seep into the corium layer or the blood capillary of the skin, and has the advantage of being fast in absorption. When the muscular soreness relieving and massaging cream is used, the skin is fine, moist and smooth. The product is convenient to carry and use and applicable to a wide range of objects.

The invention discloses a bactericide which comprises 2-methyl-methyl propionate, 2-methyl propioric acid, 1-vinyl-1-methyl-2,4-di(1-methyl vinyl)-cyclohexane, carypohyllene, 2, 6-dimethyl-6-(4-methyl-3-pentene)bicyclo[3.1.1]heptyl-2-alkenyl, 1,2,3,4,5,6,7,8-octahydro-1,4-dimethyl-7-(1-methyl ethylidene)azulene, 1,2,3,4,4a,5,6,8a-octahydro-4a, 8-dimethyl-2-(1-methyl ethyl)naphthaline, 3,3,7,11-tetramethyl tricyclo[6.3.0.0(2,4)]undecarbon-8-alkene and the like. The bactericide can be used for inhibiting or killing pathogenic microorganisms in the crop production process, mildew microorganisms of building materials and pathogenic microorganisms in human or animal living environments.

The invention belongs to the technical field of medicaments, and relates to novel azulene compounds and application thereof, in particular to novel azulene compounds which treat diseases of the immune system, have anti-aging effect and take I and II as chemical formulas. The azulene compounds have steadier structures and stronger fat solubility, and can be prepared into various pharmaceutically acceptable preparations when proper pharmaceutical excipients are matched. Immunological experimental results show that the compound I and the compound II have stronger effect on improving immune function; and antioxidation experiments show that the compound I and the compound II have stronger removal of the activity of free radicals. The azulene compounds and preparations thereof are mainly used for various diseases caused by low immunity, and can also be used for aging resistance.

The invention provides a liquid crystal compound containing dioxa saturated azulenes having a general formula (I). The compound has better chemical and physical stability, and has larger dielectric constant ad higher clearing point compared with the similar monomer containing cyclohexyl. The invention also provides a liquid crystal composition containing the novel liquid crystal compound containing dioxa saturated azulenes, and a liquid crystal element including the liquid crystal composition. The liquid crystal composition has the advantages of lower driving voltage, good low-temperature intersolubility, higher clearing point and faster response time.

This invention discloses a method for synthesizing 2-methyl azulene. The method uses molecular sieve as catalyst, and methyl cycloheptafuran-2-oxo-3-carboxylate, acetone and diethylamine at a mol ratio of 1: (15-80): (1-20), preferential 1: (25-70): (5-16) as the raw materials. The method comprises: (1) reacting mixed solution of the raw materials under refluxing, cooling to room temperature, adding water, extracting with benzene, separating, washing, recovering the solvent, and vacuum-distilling to obtain 2-methyl-azulene-1-carboxylic acid methyl ester; (2) heating in phosphoric acid to obtain 2-methyl azulene. The method has such advantages as short reaction time and high 2-methyl azulene yield.

The invention relates to the field of extraction and separation of traditional Chinese medicines, in particular to an azulene structure novel compound extracted, separated and identified from the portulaca oleracea and an extraction and separation method of the azulene structure novel compound. The azulene structure novel compound of which the molecular formula is C13H18O2 is named as Oleracone B. The invention further provides the extraction and separation method of the novel compound. According to the method disclosed by the invention, decoction with water for extraction, ethyl acetate extraction, silica gel column chromatography, ODS (Octadecylsilyl) medium pressure column chromatography and SephadexLH-20 are sequentially performed, so that the azulene structure novel compound is successfully extracted and separated. The novel compound has the effects of resisting inflammation, alleviating pains and resisting tumors. The novel compound as well as salts or derivatives thereof can be used as synthesizing precursors of other compounds, and used as raw materials for developing new medicines and researching pharmacological activity, and used for preparing medicines or health products for resisting inflammation, treating pains and resisting tumors.

The invention discloses a preparation method and application of sodium azulene sulfonate and cetylpyridinium chloride compound mouthwash and belongs to the technical field of oral cleaning and care products. The mouthwash is prepared from 0.03% of sodium azulene sulfonate (SAS), 0.05% of cetylpyridinium chloride (CPC) and the balance water. Mouthwash plays an important role in oral medicine; however, the safety performance and wound surface repairing ability of the mouthwash affect the clinical effect of the mouthwash. The anti-inflammatory and antibacterial mouthwash provided in the inventionhas an obvious repair effect on oral ulcer and is safe and capable of fast repairing the wound surface of the oral ulcer.

The invention discloses a compound oral membrane containing sodium azulene sulfonate and a preparation method. The oral membrane comprises components in percentage by weight as follows: 2%-4% of PVA0588, 1%-2% of PVA1788, 3%-6% of hyaluronic-acid-like chitosan, 2%-5% of sodium carboxymethyl cellulose, 1%-3% of Tween-80, 0.5%-2% of Tween-60, 6%-10% of glycerin, 55%-70% of distilled water, 5%-8% of a 10:1 isatis root extract, 2%-5% of vitamin B2 and 1%-4% of sodium azulene sulfonate. The oral membrane can prolong the drug acting time, has the good curative effect on targeted parts, can take effect for a longer time, can promote body recovery and enhancement of immunity and resistance, is beneficial repair of oral ulcer mucosae and has a good treatment effect on oral ulcers. Selected materials are also applied to food, wide in source and lower in product, and the product is low in preparation cost, safe to use and wider in market application range and has higher promotional value.

The invention discloses an eye film agent, wherein each 1800-2200 cm2 of the agent comprises sodium azulene sulfonate 0.1-0.5g, film-forming agent 25-40g, plasticizer 5-10ml, sterilizing water 100ml, and right amount of demoulding agent, wherein the plasticizer employs glycerine, and the demoulding agent employs fluid wax, the film-forming agent is selected from polyvinyl alcohol or methylcellulose propylene glycol ether or methyl hydroxypropylcellulose.

A capsule containing L-glutamine (C5H10N2O3) and sodium azulenylsulfonate (C15H17NaO3S.1 / 2H2O) is disclosed.

The invention discloses a compound glutamine granule and its preparing process, which consists of coating sodium azulene sulfonate with beta-cyclodextrin to obtain sodium azulene sulfonate inclusion compound, then mixing the inclusion compound with L-glutamine homogeneously, charging 3 wt% of carboxymethyl cellulose solution, stirring homogeneously to obtain soft material, finally granulating the soft material.

The invention provides an effervescent tablet for mouthwash. The effervescent tablet has effects of promoting oral cleaning, maintaining oral flora balance, repairing oral mucosal injury and inflammation and effectively preventing oral diseases. The effervescent tablet contains 5-20 parts of compound probiotics, 0.01-0.5 part of sodium azulene sulfonate, 0-0.5 part of mint and 79-95 parts of effervescent component. The effervescent tablet is prepared by uniformly mixing the components and tabletting by adopting a conventional method. The effervescent tablet is cool, refreshing and analgesic, can effectively repair oral mucosal injury, has an obvious anti-impact effect on oral inflammation, can effectively supplement oral probiotics, promotes oral flora balance, can effectively inhibit propagation and growth of oral pathogenic bacteria, and has positive significance for oral health.

A lotion containing sodium azulene sulfonate comprises, in percentage by weight, 10.5%-42% of plant extract solution or extract liquor, 0.05%-1% of the sodium azulene sulfonate and 57%-89.45% of deionized water, wherein the plant extract solution or extract liquor comprises more than two of pearl hydrolysate, Circaea lutetiana extract liquor, lemon extract liquor, aloe extract liquor, a cherry extract solution, a buckeye extract solution, coix seed extract liquor, a cactus extract solution, a soapberry extract solution, a herba portulacae extract solution, an Arnica montana extraction stock solution, a common cnidium fruit extract solution and willow bark extract. The lotion has effects of cleaning, moistening, easing, softening and converging skin, removing acne, controlling oil, whitening the kin, preserving moisture, replenishing water and the like, is used for restoring the naturally moist and elastic state of the skin, and is particularly applicable to uncomfortable skin due to season change, peeling, flaky, red and itching skin, skin getting pimples, sensitive skin and the like.